Teachers Retirement System of The State of Kentucky bought a new position in shares of Luminex Co. (NASDAQ:LMNX) during the first quarter, Holdings Channel reports. The firm bought 12,200 shares of the medical instruments supplier’s stock, valued at approximately $224,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mason Street Advisors LLC raised its position in Luminex by 0.5% in the first quarter. Mason Street Advisors LLC now owns 8,713 shares of the medical instruments supplier’s stock worth $160,000 after buying an additional 46 shares during the period. Creative Planning raised its position in Luminex by 5.4% in the first quarter. Creative Planning now owns 9,256 shares of the medical instruments supplier’s stock worth $170,000 after buying an additional 474 shares during the period. BNP Paribas Arbitrage SA raised its position in Luminex by 6.7% in the first quarter. BNP Paribas Arbitrage SA now owns 7,780 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 489 shares during the period. Sei Investments Co. raised its position in Luminex by 10.9% in the first quarter. Sei Investments Co. now owns 5,946 shares of the medical instruments supplier’s stock worth $110,000 after buying an additional 582 shares during the period. Finally, Teachers Advisors LLC raised its position in Luminex by 4.7% in the first quarter. Teachers Advisors LLC now owns 87,489 shares of the medical instruments supplier’s stock worth $1,607,000 after buying an additional 3,950 shares during the period. Institutional investors own 74.41% of the company’s stock.

Shares of Luminex Co. (NASDAQ:LMNX) traded down 0.10% on Friday, hitting $19.19. 278,696 shares of the stock traded hands. The company’s 50 day moving average is $20.59 and its 200 day moving average is $19.64. Luminex Co. has a one year low of $17.64 and a one year high of $23.62. The stock has a market cap of $845.72 million, a price-to-earnings ratio of 59.41 and a beta of 0.29.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.11. The business had revenue of $76.50 million during the quarter, compared to analyst estimates of $75.45 million. Luminex had a return on equity of 5.37% and a net margin of 7.25%. The firm’s revenue was up 19.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.33 EPS. On average, equities analysts forecast that Luminex Co. will post $0.50 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, July 14th. Stockholders of record on Friday, June 23rd were issued a dividend of $0.06 per share. The ex-dividend date was Wednesday, June 21st. This represents a $0.24 annualized dividend and a dividend yield of 1.25%. Luminex’s dividend payout ratio is 75.00%.

TRADEMARK VIOLATION WARNING: “12,200 Shares in Luminex Co. (LMNX) Acquired by Teachers Retirement System of The State of Kentucky” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/12/12200-shares-in-luminex-co-lmnx-acquired-by-teachers-retirement-system-of-the-state-of-kentucky.html.

A number of research analysts have issued reports on the stock. BidaskClub lowered shares of Luminex from a “sell” rating to a “strong sell” rating in a report on Wednesday. ValuEngine upgraded shares of Luminex from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. Zacks Investment Research lowered shares of Luminex from a “hold” rating to a “sell” rating in a report on Monday, April 17th. Jefferies Group LLC restated a “hold” rating and issued a $21.00 target price on shares of Luminex in a report on Friday, June 9th. Finally, TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a report on Friday, May 19th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Luminex has an average rating of “Hold” and an average target price of $21.67.

In related news, Director G Walter Loewenbaum II sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $20.23, for a total value of $505,750.00. Following the completion of the sale, the director now directly owns 738,896 shares in the company, valued at approximately $14,947,866.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 75,000 shares of company stock valued at $1,527,500. 6.90% of the stock is owned by corporate insiders.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.